Post-earnings recap
Reported
Wed, Aug 26, 2026
EPS actual
$0.85
EPS est.
$0.71
EPS surprise
+18.88%
1-day move
+0.45%
Phibro Animal Health Corporation reported an earnings per share of $0.85, which exceeded expectations by nearly 19%. The stock reacted positively, rising by 0.45%. However, without revenue figures or management commentary, it is difficult to assess the overall performance and outlook for the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.85 | N/A | +18.88% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±7.1%
Phibro Animal Health Corporation (PAHC) operates in the health care sector, focusing on pharmaceuticals for animal health. The company plays a crucial role in providing products that enhance animal health and productivity, which is increasingly important as global demand for livestock and poultry continues to rise.
Last quarter
In Q3-2026, Phibro reported an EPS of $0.76, exceeding expectations by 5.85%. The stock reacted positively, gaining 4.02% the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+23.55%
Avg 1-day reaction
+0.57%
Overall, expectations are mixed as the company has consistently beaten EPS estimates in the past. Investors are keen to see if this trend continues and how it will affect stock performance.
Bull case
If Phibro delivers strong EPS and shows solid revenue growth, it could lead to increased investor confidence and a significant stock price rally.
Bear case
On the other hand, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in stock price.
Key metrics to watch
Earnings Per Share (EPS)
Expecting $0.80EPS is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue Growth
Not availableRevenue growth is essential to assess the company's ability to expand its market share and meet increasing demand.
The print will turn on these.
Q1
What will the EPS be for Q4-2026?
Given the company's strong history of beating EPS estimates, this number will be crucial for investor sentiment.
Q2
What is the outlook for revenue growth in the upcoming quarters?
Revenue growth is vital for sustaining the company's market position and will be closely scrutinized by investors.
Why consensus could be wrong
The Street may be underestimating the potential for Phibro to leverage its recent product expansions, which could drive higher-than-expected revenue growth.
Supporting evidence
Phibro has consistently beaten EPS estimates, indicating strong operational management.
The options market is pricing a significant move, suggesting that traders expect volatility that could favor a positive outcome.
Recent trends in animal health demand may not be fully reflected in current analyst forecasts.
Key risk
If revenue growth exceeds expectations, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on the company's ability to maintain its growth trajectory and profitability amid market challenges.
Bull confirmed if
An EPS of $0.80 or higher would confirm the bull case and suggest strong operational performance.
Bear confirmed if
An EPS below $0.70 would signal potential issues in profitability and could confirm the bear case.
What the market is pricing for the move.
Implied Move
±22.04%
Historical Avg
±1.7%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±22.0% while PAHC has averaged ±1.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
100.6%
Smart-money positioning from the most recent 13F filings.
Institutional
103.94%
of float
Insider
0.88%
of float
Holders
308
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
3,219,040 sh · $121.4M
15.25%
-1.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Phibro beats expectations, history suggests a potential stock price increase of around 0.37% on the following day, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
A miss could lead to a decline, with historical data suggesting a potential drop of around 2.28% if expectations are not met.
The lines on the call that would change the story.
Gross Margin
Not availableGross margin will indicate how efficiently the company is producing its products and whether it can maintain profitability amid rising costs.
FMR, LLC
3,160,281 sh · $119.2M
14.97%
45.4%
State Street Corporation
1,038,382 sh · $39.2M
4.92%
9.3%
Millennium Management Llc
936,701 sh · $35.3M
4.44%
1578.1%
Vanguard Capital Management LLC
923,318 sh · $34.8M
4.37%
3.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.